| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NMTR | Common Stock | Sale | $1,144,644 | -841,650 | -3.3% | $1.36* | 24,875,105 | 23 Jun 2021 | See Footnotes | F1, F3 |
| transaction | NMTR | Common Stock | Sale | $440,572 | -319,255 | -1.3% | $1.38* | 24,555,850 | 24 Jun 2021 | See Footnotes | F1, F3 |
| transaction | NMTR | Common Stock | Sale | $19,347,750 | -15,989,876 | -65% | $1.21* | 8,565,974 | 25 Jun 2021 | See Footnotes | F1, F3 |
| holding | NMTR | Common Stock | 31,944 | 23 Jun 2021 | See Footnotes | F2, F3 |
| Id | Content |
|---|---|
| F1 | These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel GP") is the general partner of OrbiMed BioFund. |
| F2 | These shares of the Issuer's common stock are held of record by Nissim Darvish ("Darvish"). Pursuant to an agreement with OrbiMed BioFund and OrbiMed Israel GP, Darvish is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund and OrbiMed Israel GP, which will in turn ensure that such securities or economic benefits are provided to OIP. |
| F3 | This report is being jointly filed by OrbiMed BioFund and OrbiMed Israel GP. Each of the Reporting Persons and Darvish disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. |